永和智控（002795）6次甩卖子公司，从3000万元逐次降价到只有1元，这次终于有人报价了，不过最高报价只有101元…… 1月6日晚间，永和智控发布公告，关于公开挂牌转让普乐新能源科技(泰兴)有限公司(下称"泰兴普乐")51%股权及债权的进展情况。公告称，第六轮挂牌 转让期间确认一名待定受让方，最高报价101元。 公司于2025年10月10日和10月29日召开会议，审议通过了公开挂牌转让控股子公司泰兴普乐51%股权及全部债权的议案。首次挂牌的价格为3049万元，但 截止到2025年11月17日，未能征集到意向受让方。 经过多次挂牌尝试，第二次挂牌底价为2439万元，第三次挂牌底价为1829万元，第四次挂牌底价为1220万元，第五次挂牌底价为610万元，均未能吸引到 意向受让方。 最终，第六次挂牌底价降至1元，目前已确认一名待定受让方，最高报价为101元，正在进行股东征询环节，若其他股东放弃优先购买权，则该报价方将成 为受让方。 公开资料显示，永和智控主营业务是水暖阀门管件业务、肿瘤精准放射治疗业务、光伏电池业务，公司的主要产品是黄铜类有铅、无铅水/暖/燃气阀门和 近年来，永和智控业绩承压，公司2022年~2 ...

此前报道： 两资产挂牌无人问津就再打折！永和智控"割肉求生" 永和智控12月17日晚间发布的关于公开挂牌转让普乐新能源科技(泰兴)有限公司51%股权及债权的进展公告。公司于2025年10月召开的董、监事会及临时 股东大会审议通过了《关于拟公开挂牌转让普乐新能源科技(泰兴)有限公司51%股权及债权的议案》，同意公司在产权交易所公开挂牌转让控股子公司普 乐新能源科技(泰兴)有限公司(以下简称"泰兴普乐")51%股权及公司对泰兴普乐的全部债权。 公告显示，前四次公开挂牌后，均无意向受让方报名参与投资。公司继续推进公开挂牌转让泰兴普乐51%股权及债权事项，根据董事会批准及授权，挂牌 价格在首次挂牌价格(3046万元)基础上，下调80%进行第五次挂牌，第五次挂牌转让底价为609.80万元。挂牌公告期为2025年12月17日起至2025年12月23 日止。 永和智控12月17日晚间还发布了关于公开挂牌转让昆明医科肿瘤医院有限公司100%股权的进展公告。公司于2025年11月18日召开的董、监事会审议通过 了《关于拟公开挂牌转让昆明医科肿瘤医院有限公司100%股权的议案》，同意公司在产权交易所公开挂牌转让全资孙公司昆明医科 ...

Core Viewpoint - Yonghe Intelligent Control Co., Ltd. is divesting all its investments in private oncology hospitals, marking a complete exit from the healthcare sector due to ongoing financial struggles and poor performance of its medical assets [2][3][5]. Group 1: Divestment Details - Yonghe Intelligent Control has initiated the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a starting price of no less than 35.93 million yuan [3][4]. - This divestment is part of a broader strategy, as Yonghe has already attempted to sell its stakes in three other oncology hospitals since 2020, including Dazhou Medical Oncology Hospital, Liangshan High-tech Oncology Hospital, and Xi'an Medical Oncology Hospital [3][4]. - The financial performance of Kunming Medical has been poor, with revenues of 11.58 million yuan and a net loss of 6.59 million yuan for the first seven months of 2025, contributing to Yonghe's decision to sell [3][6]. Group 2: Financial Performance - Yonghe Intelligent Control's main business includes fluid control products, oncology precision radiation treatment, and photovoltaic battery production. The company reported a revenue of 1.01 billion yuan in 2021, marking a 55.71% increase [5]. - However, the company's financial situation deteriorated significantly from 2022 to 2024, with revenues declining from 990 million yuan in 2022 to 823 million yuan in 2024, and net losses increasing from 26.19 million yuan to 297 million yuan during the same period [6]. - The decline in performance is attributed to reduced income from the valve and fitting business, lower product gross margins, and high depreciation and labor costs [6][7]. Group 3: Strategic Shift - Following the divestment of its medical assets, Yonghe Intelligent Control is expected to refocus on its core business operations. The company has not yet communicated its future strategic direction or potential new growth areas [7].

Core Viewpoint - Yonghe Intelligent Control is facing significant challenges in asset divestiture and ongoing financial losses, indicating a deteriorating business situation and lack of investor interest in its assets [1][2][3]. Group 1: Asset Transfer Attempts - Yonghe Intelligent Control announced the public transfer of 51% equity in Taixing Pule and all debts owed by Taixing Pule, with an initial listing price of RMB 30.49 million, but failed to attract any interested buyers [1][3]. - Following the lack of interest, the company plans a second round of asset transfer at a reduced price of RMB 24.39 million, reflecting a 20% decrease from the initial price [1][3]. - The company's previous attempt to transfer shares held by its actual controller was also unsuccessful, as the buyer failed to make the required payment, rendering the agreement void [1][9]. Group 2: Financial Performance - Yonghe Intelligent Control has experienced a continuous decline in revenue since 2022, with reported revenues of RMB 9.90 billion, RMB 9.48 billion, and RMB 8.23 billion for the years 2022, 2023, and 2024 respectively, showing year-on-year declines of -1.86%, -4.19%, and -13.19% [2][7]. - The company reported net losses of RMB 261.87 million, RMB 1.56 billion, and RMB 2.97 billion for the same years, with losses increasing significantly year-on-year [2][7]. - For the first three quarters of 2025, Yonghe Intelligent Control reported revenues of RMB 5.82 billion, a decrease of 7.25% year-on-year, and a net loss of RMB 60.46 million, although this loss was less than the previous year's figure [8]. Group 3: Company Background and Business Operations - Yonghe Intelligent Control's main business includes water and heating valve fittings, tumor precision radiation treatment, and photovoltaic cell operations, with a focus on brass and copper products [7]. - The company acquired a 51% stake in Taixing Pule in late 2022 for RMB 31.22 million, aiming to enter the photovoltaic cell industry, but has since struggled with the performance of this investment [5][8]. - As of May 31, 2025, Taixing Pule reported a net asset value of -RMB 304 million and a debt of RMB 185 million, leading to a high debt-to-asset ratio of 211% [4].